Safety of non-vitamin K antagonist oral anticoagulants - coronary risks

Expert Opinion on Drug Safety

Volumn 15, Issue 6, 2016, Pages 731-740

  Caldeira, Daniel ^a,b,c   Ferreira, Joaquim J ^a,b   Pinto, Fausto J ^a   Costa, João ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c HOSPITAL GARCIA DE ORTA   (Portugal)

Author keywords

apixaban; dabigatran; DOACs; edoxaban; myocardial infarction; NOACs; rivaroxaban; TSOACs

Indexed keywords

APIXABAN; DABIGATRAN; EDOXABAN; PLACEBO; RIVAROXABAN; ANTICOAGULANT AGENT;

ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CORONARY RISK; DRUG SAFETY; HEART INFARCTION; HUMAN; INTERVENTION STUDY; MEDICAL HISTORY; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); CHEMICALLY INDUCED; META ANALYSIS; ORAL DRUG ADMINISTRATION; RISK;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DABIGATRAN; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84963535658     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2016.1164689     Document Type: Article

References (58)

1. S.Husted, R.De Caterina, F.Andreotti, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost. 2014;111(5):781–782.
2. T.Van Der Hulle, J.Kooiman, P.L.Den Exter, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost: JTH. 2014;12(3):320–328.
3. C.T.Ruff, R.P.Giugliano, E.Braunwald, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.•• Meta-analysis showing the overall benefit of NOACs compared to VKA in non-valvular AF.
4. D.Caldeira, M.Barra, F.J.Pinto, et al. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol. 2015 Mar;262(3):516–522.
5. D.Caldeira, F.B.Rodrigues, M.Barra, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015 Aug;101(15):1204–1211.
6. E.Z.Soliman, M.M.Safford, P.Muntner, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174(1):107–114.• Prospective cohort of 23,928 patients with a median of 4.5 years of follow-up concluded that AF is independently associated with an increased risk of incident MI.
7. J.Douxfils, F.Buckinx, F.Mullier, et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014 Jun;3(3):e000515.
8. P.Glasziou, I.Chalmers, M.Rawlins, et al. When are randomised trials unnecessary? Picking signal from noise. BMJ (Clinical Research Ed). 2007 Feb 17;334(7589):349–351.
9. B.Reeves, J.Deeks, J.Higgins, et al. Chapter 13: including non-randomized studies. In: J.P.Higgins, S.Green, editor. Cochrane handbook for systematic reviews of interventions. Wiley Online Library; 2008.
10. D.Caldeira, J.Alarcao, A.Vaz-Carneiro, et al. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ (Clinical Research Ed). 2012;345:e4260.
11. J.P.Higgins, S.G.Thompson Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 Jun 15;21(11):1539–1558.
12. G.Agnelli, H.R.Buller, A.Cohen, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708.
13. S.Schulman, C.Kearon, A.K.Kakkar, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–718.
14. R.Bauersachs, S.D.Berkowitz, B.Brenner, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510.
15. H.Ogawa, S.Goto, M.Matsuzaki, et al. Randomized, double-blind trial to evaluate the safety of apixaban with antiplatelet therapy after acute coronary syndrome in Japanese patients (APPRAISE-J). Circ J: Off J Jpn Circ Soc. 2013;77(9):2341–2348.
16. J.H.Alexander, R.D.Lopes, S.James, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699–708.
17. J.H.Alexander, R.C.Becker, D.L.Bhatt, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877–2885.
18. J.L.Mega, E.Braunwald, S.D.Wiviott, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.
19. J.L.Mega, E.Braunwald, S.Mohanavelu, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (London, England). 2009;374(9683):29–38.
20. J.Oldgren, A.Budaj, C.B.Granger, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011 Nov;32(22):2781–2789.
21. S.J.Connolly, J.Eikelboom, C.Joyner, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817.
22. M.R.Patel, K.W.Mahaffey, J.Garg, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
23. M.Hori, M.Matsumoto, N.Tanahashi, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study. Circ Journal: Official Journal Jpn Circ Soc. 2012;76(9):2104–2111.
24. C.B.Granger, J.H.Alexander, J.J.McMurray, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
25. S.J.Connolly, M.D.Ezekowitz, S.Yusuf, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
26. R.P.Giugliano, C.T.Ruff, E.Braunwald, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
27. R.Cappato, M.D.Ezekowitz, A.L.Klein, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346–3355.
28. S.Ogawa, Y.Shinohara, K.Kanmuri. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. – The ARISTOTLE-J study. Circ Journal: Official Journal Jpn Circ Soc. 2011;75(8):1852–1859.
29. M.D.Ezekowitz, P.A.Reilly, G.Nehmiz, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol. 2007;100(9):1419–1426.
30. P.Smith, H.Arnesen, I.Holme. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990;323(3):147–152.• Randomized controlled trial showing the protective effect of VKA in the prevention of acute coronary events.
31. M.Hurlen, M.Abdelnoor, P.Smith, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002 Sep 26;347(13):969–974.
32. K.W.Mahaffey, S.R.Stevens, H.D.White, et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J. 2014 Jan;35(4):233–241.
33. M.C.Bahit, R.D.Lopes, D.M.Wojdyla, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol. 2013;170(2):215–220.
34. S.H.Hohnloser, J.Oldgren, S.Yang, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125(5):669–676.•• Post hoc analysis of the RE-LY trial showing the global cardiovascular benefit of dabigatran in AF patients.
35. A.J.Camm, P.Amarenco, S.Haas, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2015.
36. T.B.Larsen, L.H.Rasmussen, A.Gorst-Rasmussen, et al. Myocardial ischemic events in ‘real world’ patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med. 2014 Apr;127(4):329–36.e4.
37. M.Avgil Tsadok, C.A.Jackevicius, E.Rahme, et al. Sex differences in dabigatran use, safety, and effectiveness in a population-based cohort of patients with atrial fibrillation. Circ: Cardiovasc Qual Outcomes. 2015 Oct 27;8:593–599.
38. T.C.Villines, J.Schnee, K.Fraeman, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015;114(6):1290–1298.
39. D.J.Graham, M.E.Reichman, M.Wernecke, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157–164.
40. J.C.Lauffenburger, J.F.Farley, A.K.Gehi, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015 Apr;4(4):e001798-e001798.
41. A.T.Cohen, S.Goto, K.Schreiber, et al. Why do we need observational studies of everyday patients in the real-life setting?: Table 1. Eur Heart J Supplements. 2015;17(suppl D):D2–D8.
42. A.Tornyos, A.Vorobcsuk, P.Kupó, et al. Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials. J Thromb Thrombolysis. 2015 Jul;40(1):1–11.
43. A.Clemens, M.Fraessdorf, J.Friedman. Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag. 2013;9:599–615.
44. K.Uchino, A.V.Hernandez. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397–402.• Meta-analysis of randomized controlled trials showing increased risk of coronary events with dabigatran.
45. S.Chatterjee, A.Sharma, K.Uchino, et al. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis. 2013 Dec;24(8):628–635.
46. Y.K.Loke, S.Pradhan, J.K.Yeong, et al. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol. 2014;78(4):707–717.• Indirect treatment comparison showing that dabigatran was associated with a significantly increased risk of adverse coronary events compared with other NOACs.
47. J.Oldgren, L.Wallentin, J.H.Alexander, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J. 2013 Jun;34(22):1670–1680.
48. K.-H.Mak. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):e001592-e001592.
49. C.P.Cannon, P.Kohli. Danger ahead: watch out for indirect comparisons! J Am Coll Cardiol. 2012 Aug 21;60(8):747–748.
50. R.Artang, E.Rome, J.D.Nielsen, et al. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol. 2013 Dec 15;112(12):1973–1979.
51. G.W.Stone, B.Witzenbichler, G.Guagliumi, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218–2230.
52. G.W.Stone, B.T.McLaurin, D.A.Cox, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21):2203–2216.
53. P.G.Steg, A.Van‘T Hof, C.W.Hamm, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;369(23):2207–2217.
54. P.G.Steg, S.K.James, D.Atar, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33(20):2569–2619.
55. N.Zemer-Wassercug, M.Haim, D.Leshem-Lev, et al. The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers. J Thromb Thrombolysis. 2015 Oct;40(3):340–346.
56. A.M.Martischnig, J.Mehilli, J.Pollak, et al. Impact of dabigatran versus phenprocoumon on ADP induced platelet aggregation in patients with atrial fibrillation with or without concomitant clopidogrel therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). Biomed Res Int. 2015;2015:798486.
57. J.A.Cairns, S.Connolly, S.McMurtry, et al. Canadian cardiovascular society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Canadian Journal Cardiology 2011 Jan-Feb;27(1):74–90.
58. A.C.Skanes, J.S.Healey, J.A.Cairns, et al. Focused 2012 update of the Canadian cardiovascular society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Canadian Journal Cardiology 2012 Mar-Apr;28(2):125–136.